Navigation Links
Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18

HPV types by 12.2% (95% CI: -3.2%, 25.3%), compared with placebo. An analysis of overall population impact for the HPV 16 L1 VLP vaccine was conducted from study 005 that had a median duration of follow-up of 3.9 years. The HPV 16 L1 VLP vaccine reduced the overall incidence of CIN 2/3 caused by vaccine or non-vaccine HPV types by 32.7% (95% CI: -34.7%, 67.3%) through a median duration of follow-up of 1.9 years (fixed case analysis) and by 45.3% (95% CI: 10.9%, 67.1%), through a median duration of follow-up of 3.9 years (end of study). GARDASIL reduced the incidence of definitive therapy (e.g., loop electrosurgical excision procedure, laser conization, cold knife conization) by 16.5% (95% CI: 2.9%, 28.2%), and surgery to excise external genital lesions by 26.5% (95% CI: 3.6%, 44.2%), compared with placebo for all HPV-related diseases. These analyses were performed in the general population of women which includes women regardless of baseline HPV PCR status or serostatus. GARDASIL has not been shown to protect against the diseases caused by all HPV types and will not treat existing disease caused by the HPV types contained in the vaccine. The overall efficacy of GARDASIL, described above, will depend on the baseline prevalence of HPV infection related to vaccine types in the population vaccinated and the incidence of HPV infection due to types not included in the vaccine. Immunogenicity Assays to Measure Immune Response Because there were few disease cases in subjects naive (PCR negative and seronegative) to vaccine HPV types at baseline in the group that received GARDASIL, it has not been possible to establish minimum anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 antibody levels that protect against clinical disease caused by HPV 6, 11, 16, and/or 18. The immunogenicity of GARDASIL was assessed in 8915 women (GARDASIL N = 4666; placebo N = 4249) 18 to 26 years of age and female adolescents 9 to 17 years of
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
2. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
3. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
4. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
5. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
6. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
7. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
8. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
9. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
10. Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
Post Your Comments:
(Date:7/11/2014)... 11, 2014 According to a ... Devices Market (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) ... Forecast, 2013-2019" the global endoscopy devices market was valued ... to grow at a CAGR of 6.8% from 2013 ... 36.9 billion in 2019. Browse the full ...
(Date:7/11/2014)... 2014 Neurelis, Inc. ("Neurelis") today announced an ... option held by Biotie to purchase Neurelis, clearing the ... (intranasal diazepam) for pediatric and adult epilepsy patients who ... year, Biotie has advanced the development program for NRL-1 ... clinical work required for NDA submission to the FDA.  ...
(Date:7/10/2014)... 2014  Breg, Inc., a premier provider of ... FreeRunner™ knee brace with new innovations to help ... return to active lifestyles.  FreeRunner,s patent-pending design acts ... support when patients need it most, and the ... Patellofemoral issues are the most common cause ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... YORK, Sept. 30 Reportlinker.com announces that a new market ... Drug Patent Inventor Report 2010 ... Report profiles the individuals, US states, and countries leading pharmaceutical ... to 2009, this report provides complete lists of: ...
... (Nasdaq: CLSN ), a leading oncology drug ... patients enrolled in its pivotal Phase III ThermoDox ® ... the Data Monitoring Committee (DMC) has unanimously recommended that ... of reaching the 600 patients required to complete the ...
Cached Medicine Technology:Reportlinker Adds Drug Patent Inventor Report 2010 2Data Monitoring Committee Unanimously Recommends Continuation of Celsion's Phase III ThermoDox® HEAT Study to Treat Primary Liver Cancer 2Data Monitoring Committee Unanimously Recommends Continuation of Celsion's Phase III ThermoDox® HEAT Study to Treat Primary Liver Cancer 3Data Monitoring Committee Unanimously Recommends Continuation of Celsion's Phase III ThermoDox® HEAT Study to Treat Primary Liver Cancer 4
(Date:7/11/2014)... New York (PRWEB) July 11, 2014 ... ) , filed against Johnson & Johnson’s Ethicon ... Bernstein Liebhard LLP notes that the Texas Attorney ... the company’s marketing of surgical mesh products used ... incontinence. According to a report from kens5.com, the ...
(Date:7/11/2014)... Dennis Thompson HealthDay Reporter ... born with HIV who was thought to be cured by ... showing detectable levels of the AIDS-causing virus in her bloodstream, ... nearly 4 years old, had remained virus-free even though she ... Doctors had hoped her remission would open the door to ...
(Date:7/11/2014)... 2014 The report, “Specialty Synthetic ... & Geography - 2018,” defines and segments the ... an analysis and forecast of the volumes and ... (Para aramids, meta aramids, UHMW Polyethylene, carbon fiber, ... fiber, PBI fiber, PBO fiber, and liquid crystal ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 ... least $50 billion in fuel costs now ... The current GHG standards are ... taken it upon themselves to install new ... , 1.    Idle reduction technologies , 2.    Efficient driveline ...
(Date:7/11/2014)... 2014 Ticket Down is a reliable ... . When it comes to the summer concert schedule, it ... Georgia native is one of the biggest names in country music ... is currently out on his “That’s My Kind of Night” tour ... tour will be making through the rest of the summer and ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3
... Set to Take Up Bill Which Includes Grants to,Train ... People,with Hearing Loss, VIENNA, Va., April 21 ... David Wu, D-Oregon, a,member of the House Subcommittee on ... in conference and vote to approve the,College Opportunity and ...
... suggests that teens may get addicted and relapse more ... motivated by drug-related cues. This conclusion has been reached ... a powerfully addicting stimulant were more likely ... it. That learned association endured: Even after experimenters ...
... of Funds in Ohio Sets Dangerous Precedent, ... preserve Ohio,s tobacco settlement dollars for their originally ... Franklin County Court of,Common Pleas for permission to ... funds, wisely dedicated by the State to,tobacco prevention ...
... leadership in premium and specialty paper market, ... that Boise BEWARE, its anti-copy/anti-scan paper, complies,with federal ... two tamper-resistant features. According to the federal mandate,for ... three,criteria by April 1. Medicaid prescription papers must ...
... April 21 NBTY, Inc. (NYSE:,NTY) (http://www.NBTY.com ), ... announced it will web cast a conference call,to review ... http://www.nbty.com on Friday, April 25, 2008 at 8:30 ... second quarter will be issued at 4:30 PM,(ET) on ...
... The National Council on Disability,(NCD) today ... Program,Performance Indicators,( http://www.ncd.gov/newsroom/publications/2008/Indicators_Report.html ),calling on the Federal ... federal data,describing the status of Americans with ... of a year-long effort. It describes what ...
Cached Medicine News:Health News:NCRA Urges Congressman David Wu to Approve in Conference the Higher Education Reauthorization Bill Providing Closed Captioning for 30 Million Deaf and Hard-of-Hearing Americans 2Health News:Rat study suggests why teens get hooked on cocaine more easily than adults 2Health News:Rat study suggests why teens get hooked on cocaine more easily than adults 3Health News:American Legacy Foundation Steps Forward to Fight For, Safeguard Ohio's Tobacco Settlement Dollars 2Health News:American Legacy Foundation Steps Forward to Fight For, Safeguard Ohio's Tobacco Settlement Dollars 3Health News:American Legacy Foundation Steps Forward to Fight For, Safeguard Ohio's Tobacco Settlement Dollars 4Health News:Boise(R) BEWARE(R) Meets April 1 Federal Medicaid Guidelines Requiring Tamper-Resistant Prescription Paper 2Health News:Boise(R) BEWARE(R) Meets April 1 Federal Medicaid Guidelines Requiring Tamper-Resistant Prescription Paper 3Health News:NBTY to Web Cast Fiscal Second Quarter Conference Call 2Health News:National Council on Disability Recommends Improving Federal Data Describing the Status of Americans with Disabilities 2Health News:National Council on Disability Recommends Improving Federal Data Describing the Status of Americans with Disabilities 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: